Researchers mapped the structural mechanisms by which bacteria regulate ribonucleotide reductase (RNR) activity via the specialized transcriptional regulator NrdR, revealing bacterial‑specific control points absent in eukaryotes. The work defines how nucleotide sensing and transcriptional modulation are coupled, highlighting NrdR and its interfaces with RNR as selective targets for next‑generation antimicrobials. Investigators argued that targeting bacterial RNR regulation could circumvent existing resistance mechanisms because the regulator is unique to prokaryotes and central to dNTP homeostasis. The findings provide a structural framework for medicinal chemistry and screening campaigns aimed at compounds that disrupt bacterial dNTP synthesis without affecting human enzymes.